全文获取类型
收费全文 | 110827篇 |
免费 | 10804篇 |
国内免费 | 2630篇 |
专业分类
耳鼻咽喉 | 1102篇 |
儿科学 | 3913篇 |
妇产科学 | 1020篇 |
基础医学 | 9043篇 |
口腔科学 | 1263篇 |
临床医学 | 15198篇 |
内科学 | 15610篇 |
皮肤病学 | 790篇 |
神经病学 | 19332篇 |
特种医学 | 3395篇 |
外国民族医学 | 4篇 |
外科学 | 9748篇 |
综合类 | 16678篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 8110篇 |
眼科学 | 1167篇 |
药学 | 10110篇 |
132篇 | |
中国医学 | 5658篇 |
肿瘤学 | 1981篇 |
出版年
2024年 | 305篇 |
2023年 | 2154篇 |
2022年 | 3320篇 |
2021年 | 5721篇 |
2020年 | 5551篇 |
2019年 | 4714篇 |
2018年 | 4328篇 |
2017年 | 4830篇 |
2016年 | 4874篇 |
2015年 | 4235篇 |
2014年 | 7675篇 |
2013年 | 8652篇 |
2012年 | 6176篇 |
2011年 | 6785篇 |
2010年 | 5466篇 |
2009年 | 5148篇 |
2008年 | 5279篇 |
2007年 | 5308篇 |
2006年 | 4630篇 |
2005年 | 3920篇 |
2004年 | 3193篇 |
2003年 | 2826篇 |
2002年 | 2442篇 |
2001年 | 2136篇 |
2000年 | 1724篇 |
1999年 | 1479篇 |
1998年 | 1323篇 |
1997年 | 1210篇 |
1996年 | 1014篇 |
1995年 | 999篇 |
1994年 | 855篇 |
1993年 | 710篇 |
1992年 | 754篇 |
1991年 | 607篇 |
1990年 | 521篇 |
1989年 | 452篇 |
1988年 | 442篇 |
1987年 | 386篇 |
1986年 | 287篇 |
1985年 | 335篇 |
1984年 | 302篇 |
1983年 | 185篇 |
1982年 | 236篇 |
1981年 | 150篇 |
1980年 | 120篇 |
1979年 | 122篇 |
1978年 | 119篇 |
1977年 | 65篇 |
1976年 | 67篇 |
1975年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Marginal rate-based analyses are widely used for the analysis of recurrent events in clinical trials. In many areas of application, the events are not instantaneous but rather signal the onset of a symptomatic episode representing a recurrent infection, respiratory exacerbation, or bout of acute depression. In rate-based analyses, it is unclear how to best handle the time during which individuals are experiencing symptoms and hence are not at risk. We derive the limiting value of the Nelson-Aalen estimator and estimators of the regression coefficients under a semiparametric rate-based model in terms of an underlying two-state process. We investigate the impact of the distribution of the episode durations, heterogeneity, and dependence on the asymptotic and finite sample properties of standard estimators. We also consider the impact of these features on power in trials designed to test intervention effects on rate functions. An application to a trial of individuals with herpes simplex virus is given for illustration. 相似文献
82.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
83.
84.
85.
86.
87.
88.
89.
目的 探讨甲状腺功能减退与子宫内膜癌(EC)的关系及EC患者癌组织分化程度和雌激素受体(ER)、孕激素受体(PR)的表达与甲状腺功能之间的关系。方法 选取2015年1月—2018年7月我院收治的EC患者113例,同时随机选取年龄与EC组相匹配的此段时间内我院健康体检的妇女156例作为对照组,检测血清促甲状腺激素(TSH)、甲状腺激素(FT4)。比较两组间甲状腺功能减退的患病率,并利用免疫组织化学法测定EC患者手术切除标本的癌组织中ER、PR的表达,分析EC患者癌组织分化程度及癌组织中ER、PR的表达与甲状腺功能之间的相关性。结果 EC组甲状腺功能减退的患病率较对照组高(P<0.000)。低分化EC患者的TSH高于中分化EC患者(P=0.025)。EC手术切除标本的癌组织中ER、PR阳性与阴性患者的TSH、FT4差异无统计学意义(P>0.05)。结论 甲状腺功能减退与EC具有相关性。 相似文献
90.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.